{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T10:38:59Z","timestamp":1767004739026,"version":"3.48.0"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Pegbing\u00ae (peginterferon alfa\u20102b), a pegylated interferon\u2010alpha, is approved for the treatment of chronic hepatitis B (CHB) and C. One of its adverse effects is platelet (PLT) suppression. It is currently being repurposed for the treatment of essential thrombocythemia (ET), a rare myeloproliferative disorder characterized by abnormally elevated PLT levels and associated with significant unmet clinical needs. The drug repositioning strategy of Pegbing\u00ae from CHB to ET aims to accelerate development and reduce costs. Through the application of pharmacometrics, the existing data from CHB patients were leveraged to inform dose selection and clinical trial design for ET patients. The pharmacokinetic\/pharmacodynamic (PK\/PD) model of Pegbing\u00ae for PLT and white blood cell (WBC) inhibition was established using data from a phase II trial conducted in CHB patients who received Pegbing\u00ae, and validated with data from a phase III trial. The PK\/PD relationship was extrapolated to ET patients by adjusting baseline PLT and WBC levels using real\u2010world data from ET patients receiving off\u2010label treatment with Pegbing\u00ae. According to the parameter distribution and correlation from the extrapolated PK\/PD relationship, 1,000 virtual ET patients were generated to form an in silico clinical trial, revealing that baseline PLT and WBC levels were key factors for hematologic response. Pegbing\u00ae 180\u2009\u03bcg is expected to be an appropriate dose for future development, with an overall complete hematologic response rate of 62.3%. A higher maintenance dose may be required in patients with severe ET. Moreover, this study provides a valuable reference for drug repositioning between two indications with significant differences.<\/jats:p>","DOI":"10.1002\/cpt.70079","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T23:39:39Z","timestamp":1759793979000},"page":"219-227","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Repositioning of Pegbing\u00ae for Essential Thrombocythemia: Insights from\n                    <scp>PK<\/scp>\n                    \/\n                    <scp>PD<\/scp>\n                    Modeling and Extrapolation"],"prefix":"10.1002","volume":"119","author":[{"given":"Weizhe","family":"Jian","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Science Peking University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yalin","family":"Yin","sequence":"additional","affiliation":[{"name":"Xiamen Amoytop Biotech Co., LTD  Xiamen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Science Peking University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsheng","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Science Peking University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianbo","family":"Gu","sequence":"additional","affiliation":[{"name":"Xiamen Amoytop Biotech Co., LTD  Xiamen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengfang","family":"Du","sequence":"additional","affiliation":[{"name":"Xiamen Amoytop Biotech Co., LTD  Xiamen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyi","family":"He","sequence":"additional","affiliation":[{"name":"Xiamen Amoytop Biotech Co., LTD  Xiamen China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2583-8080","authenticated-orcid":false,"given":"Tianyan","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Science Peking University  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00204.x"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/bit.21407"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1033"},{"key":"e_1_2_10_4_1","unstructured":"PEG\u2010Intron (Peginterferon alfa\u20102b) Package Insert [Internet]. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/pegsche080701lb.htm> Accessed January 16 2025."},{"key":"e_1_2_10_5_1","unstructured":"Pegbing (Pegintereron alfa\u20102b) package insert [Internet]. <https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=f194acc5220254c4df5c062e040f2244> Accessed January 16 2025."},{"key":"e_1_2_10_6_1","unstructured":"Besremi (ropeginterferon alfa\u20102b\u2010njft) package insert [Internet]. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/761166s007lbl.pdf> Accessed January 16 2025."},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30236-4"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017625"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-539098"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12256"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1992756"},{"key":"e_1_2_10_12_1","unstructured":"Essential thrombocythemia \u2013 symptoms causes treatment|NORD [Internet]. <https:\/\/rarediseases.org\/rare\u2010diseases\/essential\u2010thrombocythemia\/> Accessed January 16 2025."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1816082"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-643346"},{"key":"e_1_2_10_15_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology: myeloproliferative neoplasms (Version 2.2023) [Internet]. <https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf> (2024)."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-176818"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.04.004"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1403"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2143"},{"key":"e_1_2_10_20_1","unstructured":"U.S. Food and Drug Administration.Model\u2010informed drug development paired meeting program [Internet]. FDA; (2024) <https:\/\/www.fda.gov\/drugs\/development\u2010resources\/model\u2010informed\u2010drug\u2010development\u2010paired\u2010meeting\u2010program> Accessed January 17 2025."},{"key":"e_1_2_10_21_1","unstructured":"U.S. Food and Drug Administration.The Drug Development Process [Internet]. FDA; (2018) <https:\/\/www.fda.gov\/patients\/learn\u2010about\u2010drug\u2010and\u2010device\u2010approvals\/drug\u2010development\u2010process>."},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70104"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.140"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.14"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15334"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-019-09667-y"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0638-y"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0133-0"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_10_30_1","unstructured":"PhRMA.Research and development policy framework [Internet]. <https:\/\/phrma.org\/policy\u2010issues\/research\u2010development> Accessed February 14 2025."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115497"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20646"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-339002"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12759"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04484-6"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012743"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.6075"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000428"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01020-4"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27418"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004596"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T10:37:05Z","timestamp":1767004625000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/cpt.70079"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70079","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"type":"print","value":"0009-9236"},{"type":"electronic","value":"1532-6535"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"2025-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}